Compound Global Advisors LLC Sells 147,164 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Compound Global Advisors LLC cut its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 23.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 479,248 shares of the biopharmaceutical company's stock after selling 147,164 shares during the period. Royalty Pharma accounts for 2.5% of Compound Global Advisors LLC's holdings, making the stock its 18th largest position. Compound Global Advisors LLC owned about 0.08% of Royalty Pharma worth $13,462,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Park Place Capital Corp grew its stake in shares of Royalty Pharma by 52.2% in the fourth quarter. Park Place Capital Corp now owns 5,656 shares of the biopharmaceutical company's stock valued at $159,000 after acquiring an additional 1,939 shares in the last quarter. Arizona State Retirement System grew its position in shares of Royalty Pharma by 0.9% during the 4th quarter. Arizona State Retirement System now owns 104,876 shares of the biopharmaceutical company's stock worth $2,946,000 after purchasing an additional 940 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Royalty Pharma by 348.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 51,672 shares of the biopharmaceutical company's stock worth $1,451,000 after purchasing an additional 40,149 shares in the last quarter. Ballentine Partners LLC bought a new position in shares of Royalty Pharma during the fourth quarter worth approximately $341,000. Finally, State of Michigan Retirement System raised its position in shares of Royalty Pharma by 56.6% in the fourth quarter. State of Michigan Retirement System now owns 11,900 shares of the biopharmaceutical company's stock valued at $334,000 after buying an additional 4,300 shares in the last quarter. Institutional investors own 54.35% of the company's stock.

Royalty Pharma Price Performance

Royalty Pharma stock traded up $0.47 during midday trading on Friday, reaching $29.19. The company's stock had a trading volume of 2,987,665 shares, compared to its average volume of 2,667,063. The business has a 50-day moving average price of $29.83 and a 200-day moving average price of $28.38. The stock has a market cap of $17.44 billion, a PE ratio of 15.20, a price-to-earnings-growth ratio of 0.83 and a beta of 0.45. Royalty Pharma plc has a 52 week low of $25.92 and a 52 week high of $36.74. The company has a current ratio of 7.90, a quick ratio of 7.90 and a debt-to-equity ratio of 0.61.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.03 by $0.12. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. The firm had revenue of $736.00 million for the quarter, compared to analysts' expectations of $702.90 million. On average, sell-side analysts predict that Royalty Pharma plc will post 3.9 EPS for the current year.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Friday, February 16th were paid a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 2.88%. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Thursday, February 15th. Royalty Pharma's dividend payout ratio (DPR) is presently 44.44%.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. StockNews.com raised Royalty Pharma from a "hold" rating to a "buy" rating in a report on Saturday, March 30th. The Goldman Sachs Group cut their price objective on shares of Royalty Pharma from $56.00 to $50.00 and set a "buy" rating for the company in a research report on Tuesday, February 20th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Royalty Pharma from $45.00 to $42.00 and set an "overweight" rating on the stock in a report on Tuesday, February 20th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Royalty Pharma has an average rating of "Buy" and an average price target of $52.25.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.